1. "Gynecologic Medicine Service"
Formats
  1. Journal Article (1087)
  2. Meeting Abstract (890)
  3. Review (52)
  4. Book Section (46)
  5. Editorial (35)
  6. Guidelines (21)
  7. Correspondence (9)
  8. Miscellaneous (3)
  9. Research Letter (2)
  10. Book Whole (1)
Groups
  1. Gynecologic Medicine Service (2146)
  2. Solid Tumor Oncology Division (2146)
  3. Department of Medicine (2142)
  4. Gynecology Disease Management Team (1846)
  5. GDMT, Medicine (1828)
  6. Surgery (594)

More Groups

People
  1. Carol Aghajanian (607)
  2. Martee Hensley (289)
  3. Nadeem Abu-Rustum (288)
  4. Roisin O'Cearbhaill (271)
  5. Vicky Makker (263)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (41)
  2. 2024 (167)
  3. 2023 (171)
  4. 2022 (209)
  5. 2021 (163)
  6. 2020 (203)

More Years

Publications
  1. Journal of Clinical Oncology (450)
  2. Gynecologic Oncology (418)
  3. International Journal of Gynecological Cancer (154)
  4. Annals of Oncology (116)
  5. Clinical Cancer Research (67)
  6. Cancer Research (55)

More Publications

Publishers
  1. Elsevier Inc. (542)
  2. American Society of Clinical Oncology (489)
  3. Lippincott Williams & Wilkins (181)
  4. American Association for Cancer Research (168)
  5. Oxford University Press (143)
  6. Nature Publishing Group (86)

More Publishers

Results (2146)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Germline SDHA mutations in children and adults with cancer
    Journal Article

    Dubard Gault, M.; Mandelker, D.; Delair, D.; Stewart, C. R.; Kemel, Y.; Sheehan, M. R.; Siegel, B.; Kennedy, J.; Marcell, V.; Arnold, A.; more...
    Cold Spring Harbor Molecular Case Studies (2018)

    Fulltext@MSK | Save
  • Resource utilization early after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J. H.; Sauter, C. S.; Duck, E.; Halton, E.; Palomba, M. L.; Batlevi, C. L.; Younes, A.; Geyer, M. B.; Smith, E. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial
    Meeting Abstract

    Moore, K. N.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC)
    Meeting Abstract

    O'Cearbhaill, R. E.; Wolfer, A.; Disilvestro, P.; O'Malley, D. M.; Sabbatini, P.; Shohara, L.; Schwarzenberger, P. O.; Ricciardi, T.; Macri, M.; Ryan, A.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Subgroup analysis of rucaparib in platinum-sensitive recurrent ovarian carcinoma: Effect of prior chemotherapy regimens in ARIEL3
    Meeting Abstract

    Lorusso, D.; Coleman, R. L.; Oza, A. M.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J. I.; Clamp, A. R.; Scambia, G.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Phase 1 study using mogamulizumab (KW-0761) to deplete regulatory T cells in combination with checkpoint inhibitors durvalumab (MEDI4736) or tremelimumab in subjects with advanced solid tumors
    Meeting Abstract

    Zamarin, D.; Hamid, O.; Nayak, A.; Sahebjam, S.; Sznol, M.; Collaku, A.; Fox, F.; Marshall, M.; Hong, D.
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save
  • HLA class I subtypes are associated with immune-related adverse events in patients with melanoma treated with ipilimumab
    Meeting Abstract

    Safonov, A.; Pluta, J.; Qian, L.; Amaravadi, R.; Applegate, A.; Buchbinder, E.; Cohen, J.; Friedman, C.; Halaban, R.; Hodi, F. S.; more...
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save
  • Intestinal microbiota composition prior to CAR T cell infusion correlates with efficacy and toxicity
    Meeting Abstract

    Smith, M.; Littmann, E. R.; Slingerland, J. B.; Clurman, A.; Slingerland, A. E.; Taur, Y.; Schluter, J.; Park, J. H.; O'Cearbhaill, R.; Mailankody, S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial
    Meeting Abstract

    Friedlander, M.; Moore, K.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer
    Journal Article

    Moore, K.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
    New England Journal of Medicine (2018)

    Fulltext@MSK | Save